Deep Dive 2026 · Biotech & Healthcare
Nasdaq: $OMER
Omeros ($OMER): The Biotech With No Perfect Peer
YARTEMLEA turned Omeros into a commercial company, and a single sales multiple still gives the wrong answer. The equity combines an early rare-disease launch, a contested European path, complement-platform optionality, contingent Novo Nordisk economics and a capital structure that has to be rebuilt from the footnotes.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
$OMER daily chartSource: Finviz — informational only, not a recommendation.
At a glance — market data at the close of August 26, 2026
Close, August 26, 2026
$18.22
Finviz Elite daily close
Basic equity value
$1.319B
72,388,316 shares, 10-Q cover
Q2 net product sales
$28.5M
H1 2026 $38.4M
Mechanical annualization
$114.1M
Q2 times four, not a forecast
Cash at June 30
$132.0M
cash plus short-term investments
Post-July mechanical cash
$71.6M
after $60.4M of note repurchases
Convertible principal
$40.3M
6.525M shares on conversion
Enterprise value multiple
11.3x
against the annualized denominator
Nasdaq: $OMERTA-TMA after stem-cell transplantMASP-2 / lectin pathwayFDA approved December 23, 2025CHMP opinion negative, re-examination openNTAP effective October 1, 2026Novo Nordisk milestones retainedNo price target published
Highest-impact open event
EMA re-examination of the negative CHMP opinion, no date fixed
The CHMP adopted a negative opinion on June 25, 2026 and the procedure moved to re-examination, recorded on the EMA product page as of July 15, 2026. No conclusion date is published. On August 12, 2026 the company disclosed that an Ad Hoc Expert Group of external hematology and transplant specialists will review the evidence as part of the procedure. The operative status is refusal maintained while the re-examination runs.
Capital structure after the July repurchases
Cash of $71.6M on the mechanical bridge, $40.3M of convertible principal left
Balance-sheet figures only: $132.0M of cash and short-term investments at June 30 less $60.4M paid in July, $40.3M of principal outstanding at July 20 with 6.525M shares on conversion, 16.2M options outstanding at June 30 plus roughly 3.1M awarded on July 22, a $150M ATM facility still untouched, and $90.1M left on the share repurchase authorization.
01 Why a single sales multiple gives the wrong answer
Omeros crossed the line that matters most in biotech on December 23, 2025, when the FDA approved YARTEMLEA (narsoplimab-wuug) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy, or TA-TMA, in adults and children two years and older. First commercial shipments followed in January 2026. Net product sales moved from $9.9 million in the first quarter of shipments to $28.5 million in the second. The company is no longer a development-stage story with a binary outcome attached to it.
It is also not yet a predictable rare-disease compounder, and that is where valuation gets difficult. Applying one revenue multiple to $28.5 million of quarterly sales answers a question nobody is actually asking, because the equity is a bundle of five separate claims that carry different probabilities and different owners.
The five parts. One, the U.S. YARTEMLEA franchise, which has two commercial quarters of history. Two, a European option that currently sits behind a negative CHMP opinion under re-examination. Three, the retained complement and CNS pipeline, which has mechanism but no human efficacy. Four, contingent milestones and royalties on zaltenibart, now developed and controlled by Novo Nordisk. Five, the net capital structure: convertible notes, options, an unused ATM facility and an OMIDRIA royalty arrangement that has an asset and an obligation on the same balance sheet.
Both simplistic readings fail. A bear who annualizes the latest quarter and applies a mature-drug multiple ignores four of those five parts. A bull who adds the $2.1 billion of headline Novo milestones to the commercial franchise counts money that is contingent, externally controlled and, in the case of the $240.0 million upfront, already received and already spent on debt and operations. Adding unlike claims produces a precise number and a false one.
The parts separate as follows: what can be priced is priced, and the pieces that cannot yet be valued with the disclosure that exists are named as such.
02 What the current price appears to require
At the $18.22 close on August 26, 2026, and using the 72,388,316 shares reported outstanding on the cover of the June 2026 Form 10-Q, basic equity value is approximately $1.319 billion. The enterprise-value bridge starts from $132.0 million of cash, cash equivalents and short-term investments at June 30, subtracts the $60.393 million of cash that left in July for the two note repurchases and accrued interest, and adds back the $40.322 million of convertible principal still outstanding. That produces roughly $1,288 million.
Treating the remaining notes as converted instead of repaid gives a different but equally legitimate view: 78.913 million shares at the same price, less the same post-July cash, for about $1,366 million. Neither figure is a pro-forma balance sheet. Both exclude operating cash movements after June 30 and neither nets the OMIDRIA royalty asset against its funding obligation.
| Bridge component | Amount | Source and date |
|---|---|---|
| Basic equity value (72,388,316 shares at $18.22) | $1,318.9M | 10-Q cover page, August 7, 2026; close of August 26, 2026 |
| Cash and short-term investments | $132.0M | Balance sheet, June 30, 2026 |
| July cash outflow for note repurchases and interest | ($60.393M) | Subsequent events, 10-Q |
| Mechanical post-July cash | $71.56M | Arithmetic, excludes operating movements |
| Convertible principal outstanding | $40.322M | Repurchase table, at July 20, 2026 |
| Indicative enterprise value, basic | $1,288M | Equity plus notes less post-July cash |
Against the purely mechanical annualization of second-quarter sales, $114.1 million, that enterprise value is about 11.3 times. The mechanical annualization is not a forecast and the multiple is not a fair-value conclusion. It is an expectations test, and the useful number it produces is the residual: roughly $1,174 million of value sits above a flat continuation of the second quarter.
What the residual has to be made of. Some combination of sustained launch growth, attractive normalized margins after preapproval inventory is exhausted, European or new-indication value, Novo milestone and royalty cash, and value from the retained pipeline. If several of those fail at once, there is little operating protection underneath the multiple.
One methodological note, because it changes the answer materially. Market-data providers have displayed a higher market capitalization for Omeros using a diluted share basis. Basic equity value above comes from the actual SEC share count, and potential note conversion and options are shown separately, so that debt is not double-counted and dilution is not hidden inside a single headline. For reference, the company’s own reported diluted weighted-average share count was 89.6 million for the second quarter, against basic weighted-average shares of 72.1 million and the 78.913 million used in the conversion scenario above, because the diluted figure also applies the treasury-stock method to options.
03 YARTEMLEA: the commercial line that must hold
TA-TMA is a severe endothelial-injury syndrome after transplant. It can involve anemia, low platelets, hemolysis, kidney damage, respiratory failure and other organ dysfunction, and it arrives in patients who are frequently already managing infection and graft-versus-host disease. Diagnosis is complex, treatment decisions are concentrated in transplant centers and the money flows through institutions rather than retail pharmacy.
That is why a hospital launch does not look like a chronic retail launch, and why two quarters of revenue growth is a real signal but not yet a curve. Second-quarter gross product sales were $32.2 million with gross-to-net deductions disclosed at approximately 11.5%, and reported cost of sales was only $0.798 million. That last figure is the one most likely to be misread: much of the preapproval inventory had already been expensed through research and development before approval, so the first reported gross margin is not a steady-state economic margin and should not be projected forward as one.
Dosing makes revenue quality harder to read
Under the label, patients weighing at least 50 kilograms receive 370 mg intravenously once weekly over 30 minutes, with the option to increase to twice weekly if improvement in TA-TMA signs and symptoms is inadequate. Patients under 50 kilograms receive 4 mg/kg on the same schedule. The label sets no fixed treatment duration; in the pivotal study, median therapy ran eight weeks with a range of two to 16.4 weeks.
Revenue can therefore rise for three different reasons: more patients treated, longer treatment per patient, or higher dosing intensity in patients who respond inadequately. Only the first is unambiguously a breadth-of-adoption signal, and the filings do not yet disclose the patient-level detail needed to separate them.
The metrics that would settle it. Activated transplant centers, new versus repeat orders, time from diagnosis to first dose, first-line versus rescue positioning, average doses per patient, discontinuation patterns, gross-to-net evolution and the adult-versus-pediatric split. None of these is currently reported. Until they are, sequential revenue is the only available proxy, and a single quarter of it proves less than it appears to.
The first two commercial quarters. First shipments began in January 2026.
$9.9MQ1 2026first quarter of shipments
$28.5MQ2 2026first full quarter
Source: SEC Form 10-Q and second-quarter release, June 30, 2026
04 Reimbursement architecture: J1289 and the FY2027 NTAP
Two reimbursement mechanics improved during 2026, in stages, and both are frequently overstated.
The permanent HCPCS code J1289 became effective on July 1, 2026. A permanent J-code removes the billing friction of miscellaneous codes and makes claims processing routine. It simplifies payment; it does not create demand.
CMS then granted New Technology Add-on Payment status for fiscal 2027, effective October 1, 2026, with a maximum add-on payment of $287,079 for eligible Medicare inpatient cases. The economics of that need stating precisely, because the most common error in retail commentary is to treat it as revenue to Omeros.
Who receives the NTAP. The add-on payment goes to the hospital, not to Omeros, and it does not change the amount Omeros receives for YARTEMLEA. It applies only to eligible inpatient cases, and the amount actually paid follows the lesser-of formula rather than the maximum in every case. Its effect on the company is indirect: better hospital economics can reduce the budget objection to treating a patient.
| Mechanism | Effective | Who benefits directly | What it does not do |
|---|---|---|---|
| Permanent HCPCS code J1289 | July 1, 2026 | Billing departments and payers | Does not create patient demand or coverage |
| FY2027 NTAP, maximum $287,079 | October 1, 2026 | Hospitals treating eligible Medicare inpatients | Does not increase Omeros’ price or revenue per patient |
| Existing outpatient and commercial coverage | Ongoing | Varies by payer and site of care | Not uniform, and not disclosed case by case |
Both changes are implemented facts rather than pending catalysts. Their value shows up, if at all, in the third and fourth quarters, through the pace of center activation and the share of eligible patients actually treated.
05 The pivotal evidence, read exactly as it stands
Mechanism, in plain language. MASP-2 is an effector enzyme in the lectin pathway of complement. Narsoplimab binds MASP-2 and is designed to dampen lectin-pathway activation while leaving the classical and alternative pathways intact. That selectivity is a mechanistic property. It is not, by itself, evidence of better efficacy or of fewer infections than C5 inhibition.
The central study was an open-label, single-arm pivotal trial in 28 adults with HSCT-TMA (NCT02222545). Twenty-four patients received 4 mg/kg intravenously once weekly for either four or eight weeks, and four received 370 mg once weekly for eight weeks. The primary response endpoint was composite and demanding: improvement in both laboratory markers of TMA, platelets and LDH, plus improvement in organ function or transfusion independence. Seventeen of 28 patients responded, 61%, with a 95% confidence interval of 40.6% to 78.5%.
Two survival figures exist for the same study
The Journal of Clinical Oncology paper reports 100-day survival after TA-TMA diagnosis of 68% in the full analysis set and 94% among responders. The FDA label reports 73.4% (95% CI 52.2–86.4) for 100-day survival in the same study, and does not carry the responder figure. Both are primary sources and both are correct within their own framing; they are not interchangeable, and every survival number below carries the document it comes from.
The responder figure carries an additional caveat that applies regardless of source: responders are a post-baseline subgroup, and subgroup survival benefits from selection. Patients who survive long enough to respond are, definitionally, doing better than those who do not.
What the design does and does not support
There was no randomized concurrent control, the sample was small, and supportive care in TA-TMA varies across transplant centers. The FDA judged the total evidence package sufficient for approval, combining the pivotal study with expanded-access experience, pharmacology, safety and the absence of any approved alternative. Both facts hold simultaneously: the drug is fully approved for the labeled population, and the comparative magnitude of benefit is less certain than it would be after a randomized trial. The approval letter also carries a postmarketing requirement under section 505(o) for a registry of at least 50 patients with one-year follow-up, final protocol due in December 2026 and completion targeted for 2033.
Real-world experience points the same direction, without solving the control problem
Castelli and colleagues published a 20-patient compassionate-use cohort in Bone Marrow Transplantation in 2024: 13 of 20 responded, 65%, with 100-day overall survival of 70% after TA-TMA diagnosis and 100% among responders. Schoettler and colleagues analyzed 136 adults and children from the expanded-access program in the American Journal of Hematology in 2025, reporting one-year survival stratified by age, risk and line of therapy, with children defined as under 16 years. Neither study has a control arm, treatment selection is not random, and sponsor involvement is part of the context.
Three different patient counts, three different documents. The FDA label describes 221 adults and children treated under expanded access, of whom 19 had patient-level response data that entered the efficacy analysis. The Schoettler paper analyzes 136. The EMA assessment describes the data presented to it as 27 adults and 16 children. These are different cuts of the same program, and each figure only means something next to its own source.
06 Safety in a population that is already critically ill
In the 28-adult safety dataset, the label reports serious adverse reactions in 61%, serious infections in 36% and fatal adverse reactions in 7%, the latter comprising neutropenic sepsis and septic shock. Adverse reactions occurring in at least 20% of patients, tabulated regardless of causality, were viral infection, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue and hypokalemia. Dose interruptions for adverse events occurred in 7%.
These numbers require reading in both directions. Presenting them as though YARTEMLEA caused every tabulated event misstates a dataset that records events regardless of causality in patients who are post-transplant and frequently infected. The opposite spin is equally wrong: the absence of a boxed warning and the absence of a REMS do not mean the absence of serious infection risk, and the label carries a specific warning for serious infections. The expanded-access safety population comprised 221 adults and children, with a median of eight doses over 5.5 weeks, and the label states that no new clinically significant safety signals were identified.
07 C5 inhibition, and why cross-trial comparison fails
Eculizumab has been used off label in TA-TMA for years, which makes C5 inhibition the practical comparator in most transplant centers even though it carries no TA-TMA indication.
A systematic review and meta-analysis by Zhang and colleagues, published in Frontiers in Immunology in 2021, pooled 116 patients across six mainly observational studies and estimated a 71% overall response rate (95% CI 58–82), a 32% complete response rate (95% CI 11–56) and 52% survival at last follow-up (95% CI 40–65), with substantial heterogeneity. A 2025 Mayo Clinic series by Acosta-Medina and colleagues described 99 adult TA-TMA cases diagnosed between 2005 and 2022, an incidence of 6.2% after allogeneic transplant at a median of 137 days, and 11 patients treated with eculizumab with an observed 70% overall response rate including five complete responses.
Why the tempting comparison is not available. A 71% pooled response rate in observational eculizumab studies and a 61% composite response rate in a single-arm narsoplimab trial are not measuring the same thing. The response definitions differ, the populations differ, the timing of treatment differs, supportive care differs across two decades of practice, and the eleven eculizumab patients in the Mayo series are far too few for any cross-drug conclusion. Anyone presenting one number as larger than the other is comparing endpoints, not drugs.
AstraZeneca reported on July 27, 2026 that ALXN1210-TMA-313, the randomized, double-blind, placebo-controlled Phase 3 trial of ravulizumab in 146 adult and adolescent HSCT-TMA patients, did not achieve statistical significance on its primary endpoint of 26-week event-free survival, defined as time from randomization to TMA-related clinical worsening or death. The company described a trend toward treatment benefit and discussions with regulators. In the separate single-arm pediatric study of 41 patients it reported overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks, and it is proceeding with pediatric regulatory filings supported by an externally controlled study; the release does not state whether the pediatric primary endpoint of complete TMA response at 26 weeks was met.
That failed adult trial reduces the probability of a clean near-term on-label adult competitor. It does not validate narsoplimab, and it establishes no head-to-head superiority. Pediatric competition remains a live possibility.
08 Europe: an adverse opinion under re-examination
The CHMP adopted a negative opinion on Yartemlea on June 25, 2026, and the marketing-authorisation application, filed by Omeros Ireland Limited under procedure EMEA/H/C/005247, moved to re-examination. The EMA product page, last updated on July 15, 2026, records the status as opinion under re-examination and states that the company has requested it. The page gives no expected conclusion date. In its second-quarter release on August 12, 2026, Omeros disclosed that an Ad Hoc Expert Group, expected to comprise external scientific and clinical experts in hematology and stem-cell transplantation, will review the evidence and address the questions central to the CHMP assessment, and that the drug remains available to European transplant physicians through an expanded-access program that prioritizes children with TA-TMA.
Status discipline. The correct description is that the negative opinion stands while re-examination proceeds. There is no reversal, no approval and no published timetable. Any bear case must continue to assume the refusal is maintained, and any bull case that treats Europe as recovered is describing something the file does not say.
What the CHMP actually objected to
The committee’s stated grounds are unusually specific and they matter for how a re-examination could plausibly succeed. The evidence of efficacy was judged insufficient. The main study was not comparative against placebo or another treatment and patients received concomitant therapies, so the observed benefits could not be attributed to narsoplimab. The committee raised concerns about study conduct, including changes made during the study, how efficacy was measured and dose selection. It noted published literature showing similar results with other treatments, considered the survival comparison against external patients unreliable, found the data insufficient to establish dose, efficacy and safety in children, and concluded that the results did not confirm the expected mechanism of action in the disease.
Several of those objections are structural rather than presentational. A re-examination can add analyses, expert argument and context, and the Ad Hoc Expert Group is the forum where that argument gets its hearing, but no procedure can retroactively create a control arm. That is the single most important reason to keep the European probability weighted rather than assumed.
09 Q2 financials: the first period that paid for its own costs
Second-quarter results are the first genuine operating proof point in the company’s history as a commercial business, and they are stronger than most launches at this stage.
| Line | Q2 2026 | H1 2026 | What it means |
|---|---|---|---|
| YARTEMLEA net product sales | $28.529M | $38.422M | Q1 reported at $9.9M; $9.893M is the exact figure implied by the two published periods |
| Cost of product sales | $0.798M | $1.385M | Flattered by preapproval inventory already expensed through R&D |
| Research and development | $13.798M | — | Lower than the pre-approval years, still substantial |
| Selling, general and administrative | $13.859M | — | Carries the launch infrastructure |
| Income (loss) from operations | $74K income | ($17.347M) | Commercial revenue covered reported operating costs in Q2 |
| Cash from operations | $4.1M provided | ($10.357M used) | Sequential swing of roughly $18.6M |
| GAAP net income | — | $69.292M | Includes $84.593M of non-cash fair-value gain |
Why GAAP net income is useless for valuation here
The $69.3 million of first-half net income includes a $84.6 million non-cash gain from changes in the fair value of financial instruments, driven mainly by the embedded derivative in the 2029 notes. The company’s own non-GAAP reconciliation removes exactly that amount and arrives at an adjusted loss of $15.301 million. A price-to-earnings ratio built on the GAAP figure measures a derivative mark, not a business.
The direction of that mark matters for the quarters ahead. The June valuation used a share price of $9.51 and carried the embedded derivative down from $157.2 million at December 31, 2025 to $55.2 million at June 30, 2026, against $17.18 at the earlier date. At the $18.22 close used throughout these pages the input is well above both, so a non-cash movement of comparable scale runs the other way, and third-quarter GAAP earnings will be no more informative about the business than the first half was.
The informative indicators are product revenue, normalized gross margin once preapproval inventory is exhausted, operating expenses, operating cash flow, and how many quarters the current capital supports under different launch paths. Runway cannot honestly be expressed as cash divided by last-quarter burn, because the denominator changed sign during the quarter and the numerator changed materially after quarter end.
Cost of sales is small because much of the preapproval inventory was already expensed through research and development.
$28.5M
total Q2 costs
- Selling, general and administrative$13.859M48.7%
- Research and development$13.798M48.5%
- Cost of product sales$0.798M2.8%
Source: SEC Form 10-Q, June 30, 2026
Arithmetic only. It excludes every operating cash movement after June 30 and is not a pro-forma balance sheet.
$132.0MJune 30, 2026cash and short-term investments
($60.4M)July repurchasesprice plus accrued interest
$71.6MMechanical residualbefore operating movements
Source: SEC Form 10-Q, balance sheet and subsequent events
10 Capital structure: what the July repurchases actually did
Two privately negotiated repurchases of the 2029 convertible notes closed in July 2026: one agreed on June 17 and closed July 6, retiring $16.000 million of principal for $31.259 million plus $89 thousand of interest; a second agreed July 2 and closed July 20, retiring $14.463 million for $28.911 million plus $134 thousand. Total principal retired was $30.463 million for $60.170 million of cash plus $0.223 million of interest.
The arithmetic that gets misquoted. Cash out was roughly $60.4 million; principal down was $30.5 million. The company paid close to two dollars of cash for each dollar of face value, which is what happens when a convertible is deep in the money. The transaction removed dilution, and it was expensive. Describing it as “debt fell by $60 million” is wrong in both directions.
What remains: $40.322 million of principal outstanding at July 20, associated with approximately 6.525 million shares on conversion, down from 11.454 million at the end of 2025. Options outstanding at June 30 numbered 16.2 million at a weighted-average exercise price of $7.51. Of those, 12.3 million were already exercisable, and 6.7 million carried strikes above $9.51, which was the closing price on June 30; the two groups overlap. At the $18.22 close of August 26, 2026 essentially the whole stack is in the money. Approximately 3.1 million further options were awarded on July 22 for the 2025 performance period. The $150 million ATM facility remains fully available, with no shares sold during the first half of 2026.
Capital allocation has not run in one direction only. A separate $100 million share repurchase authorization approved by the board on November 29, 2025 remains in place: the company retired approximately 0.8 million shares during the first half of 2026 at an average cost of $11.70 per share, for $9.9 million, and disclosed $90.1 million still available under the authorization as of August 12, 2026.
Options are deliberately not added one-for-one into a single fully diluted count here. Treasury-stock dilution depends on strike prices and exercise proceeds, and the filing does not support one clean aggregate incremental-share figure at the current price. The honest statement is that the option stack is large relative to a 72 million share base, that a strong share price makes ATM issuance rational even when it is not immediately necessary, and that the repurchase authorization pulls the other way for as long as management chooses to use it.
11 OMIDRIA: an asset and an obligation in the same sentence
The June balance sheet carries OMIDRIA contract royalty assets of $25.603 million current and $90.875 million non-current, $116.5 million in total, against royalty obligations of $21.511 million current and $136.370 million non-current, $157.9 million in total. The gross asset is therefore $41.4 million smaller than the gross obligation.
The structure behind those lines: Omeros sold OMIDRIA royalty rights to DRI Healthcare Acquisition LP in September 2022 for $125.0 million, and in February 2024 DRI purchased the remaining U.S. royalties through December 31, 2031 for a further $115.5 million in cash under an amended agreement that removed the annual caps. U.S. royalties received from Rayner flow to an escrow account and from there to DRI. The obligation amortizes to the end of 2031 at an implied effective rate of 10.27%, while the royalty asset accretes interest at 11.0%.
Why it belongs outside the cash line. The royalty asset is not liquidity available to fund the YARTEMLEA launch, and the obligation is not ordinary debt that can be netted at face value. Adding the asset to cash overstates resources; subtracting the whole obligation as debt overstates leverage. Until the waterfall, timing and discount rates are reconstructed, the arrangement belongs outside both the cash line and the debt line, as a separate structured claim.
12 Novo Nordisk: economics that cannot be booked twice
The zaltenibart transaction closed on November 25, 2025. Omeros received a $240.0 million upfront cash payment and became eligible for up to $510.0 million in one-time development and approval milestones, including $100.0 million that the company expects to be achievable in the near term, plus up to $1.3 billion in sales-based milestone payments and tiered royalties on annual net sales at percentage rates ranging from high single digit to high teens, subject to reduction in certain circumstances. The filing states the headline as up to $2.1 billion in potential development and commercial milestones; the itemized amounts disclosed are the $510.0 million and the $1.3 billion, which together with the $240.0 million upfront come to $2.05 billion.
Novo obtained global rights and controls development, spending and timing. Omeros retained its entire MASP-3 small-molecule program across several therapeutic areas, and retained its “grandfathered” MASP-3 antibodies subject to temporal and indication restrictions on commercialization.
Three ways this gets double counted. Adding $2.1 billion of contingent payments to market capitalization treats probability-weighted claims as cash. Counting the $240.0 million upfront as future value ignores that it has already funded debt retirement, note repurchases and operations. Describing the $1.3 billion as commercial milestones without saying they are sales-based implies they arrive on approval rather than on volume. A defensible valuation discounts each stream separately for probability and timing, and remembers that the timing is somebody else’s decision.
Only the upfront has been received. Novo controls development, spending and the timing of every milestone.
$2.05B
the three amounts above
- Sales-based milestones, contingent$1.30B63.4%
- Development and approval milestones, contingent$510M24.9%
- Upfront, already received and deployed$240M11.7%
Source: SEC Form 10-Q, Note 1, and the closing announcement of November 25, 2025
13 The retained pipeline, valued conservatively
| Asset or right | Area | Status | What could create value | Main uncertainty |
|---|---|---|---|---|
| YARTEMLEA / narsoplimab | TA-TMA after HSCT, age 2 and older | FDA approved, U.S. launch under way; negative CHMP opinion under re-examination | Center activation, repeat use, reimbursement, European outcome | Durability of the launch curve and comparative evidence |
| OMS1029 | Long-acting MASP-2 antibody | Phase 1 single and multiple ascending dose work completed | Quarterly intravenous or subcutaneous dosing could open chronic complement indications | No Phase 2 indication selected and no human efficacy signal disclosed |
| Oral MASP-2 inhibitor | Undisclosed complement-mediated uses | Preclinical | Oral dosing would extend the platform beyond infused antibodies | Very early, no defined development path |
| Zaltenibart economics | MASP-3 / alternative pathway, led by Novo | Rights transferred, contingent economics retained | Up to $510M development and approval milestones, $1.3B sales-based, tiered royalties | Entirely contingent; Novo controls timing and spending |
| OMS527 | PDE7 inhibitor, addiction research | Early clinical, NIDA-supported | External funding preserves optionality at low company cash cost | Long path, uncertain indication and partnering economics |
| OncotoX-AML and T-CAT | Oncology and multidrug-resistant pathogens | Preclinical | Platform optionality or future partnership | Should carry little present value before translational validation |
The pipeline is real science with genuine optionality, and it is also the part of the sum of the parts most likely to be over-credited. Mechanism plus early pharmacology is not a valuation input until an indication, a trial design, an endpoint and a budget exist.
14 Ownership and insider alignment
The 2026 definitive proxy, using 72,168,330 shares outstanding at the April 17, 2026 record date, reports chief executive Gregory A. Demopulos with 5,880,350 shares beneficially owned, 7.7% of the class, of which 4,411,042 are exercisable stock options. Peter A. Demopulos holds 1,072,898 shares, 1.5%, including 100,000 exercisable options.
Insider alignment is therefore material, but the composition matters: most of the chief executive’s disclosed beneficial position consists of exercisable options rather than purchased common stock, so the headline percentage should not be read as cash at risk equal to the full count.
On the institutional side the proxy lists BlackRock with 4,279,836 shares, 5.9%. That figure is derived from a Schedule 13G filed in January 2024 and reflects a position as of December 31, 2023; the filing itself carries the caveat that the holding may have changed since. Vanguard was removed from the table after an amendment in March 2026. No current 13F-based ownership trend is asserted, because no complete live aggregation of those filings was performed.
15 The peer stack: who Omeros can actually be compared with
The answer is a stack, not a ticker. Each group answers a different question, and no single company answers all of them.
| Company | Role in the comparison | Operating fact, Q2 2026 | Equity value at the August 26, 2026 close | Why it helps and where it breaks |
|---|---|---|---|---|
| Omeros $OMER | Subject | YARTEMLEA net sales $28.5M; mechanical annualization $114.1M | $1,319M | Early commercial franchise plus contingent and pipeline options |
| Zevra $ZVRA | Closest commercial anchor | MIPLYFFA net sales $30.2M; total revenue $39.7M; liquidity $260.2M | $697M | Also launched a first-in-disease rare product at a similar quarterly scale; different disease, dosing and market structure |
| Annexon $ANNX | Complement science, pre-revenue | No product revenue; cash and short-term investments $209.2M | $946M | Shows what late-stage classical-complement programs are worth without commercial proof |
| Dianthus $DNTH | Aspirational complement platform | No product revenue; cash and investments about $1.2B; Phase 3 EMERGE in gMG started June 2026 | $6.20B | Premium pipeline comparator with unusual capital; too rich and too different to anchor $OMER |
| InflaRx $IFRX | Negative control | No product revenue; cash about $171M (€146.6M), total liquidity about $185M (€158.4M) including marketable securities, converted at 1.1649 | $357M | Complement biology alone is not a valuation category without asset quality and execution |
| BioCryst $BCRX | Commercial maturity check | Product sales $157.5M; cash and investments $352.6M | $2.51B | Established rare-disease commercial base, much larger and differently composed |
| Travere $TVTX | Upper commercial check | FILSPARI net sales $141.1M; cash and marketable debt securities $489.2M | $6.33B | What a de-risked growth franchise is worth; not a TA-TMA or complement comparator |
Equity values are computed from the share count in each company’s most recent SEC filing, the 10-Q cover page where one exists and the most recently reported count otherwise, multiplied by the August 26, 2026 close, so that all seven are measured on the same day. InflaRx deserves a specific warning: its share count moved from 72.3 million at the start of 2026 to 147,368,221 at June 30 after a 75 million share offering at $2.00 completed in May 2026. Using the pre-offering count of 72,292,859 shares produces a market value of roughly $175 million and a peer comparison that is wrong by a factor of about two.
Shares from each company's most recent SEC cover page, multiplied by the August 26, 2026 close.
Travere Therapeutics ($TVTX)$6.33B
FILSPARI franchise
Dianthus Therapeutics ($DNTH)$6.20B
pre-revenue complement platform
BioCryst ($BCRX)$2.51B
established rare-disease sales
Omeros ($OMER)$1.32B
two commercial quarters
Annexon ($ANNX)$946M
pre-revenue
Zevra ($ZVRA)$697M
closest launch-stage peer
InflaRx ($IFRX)$357M
post-offering share count
Source: SEC filings and Finviz Elite closing prices
16 The multiple screen, and what it does and does not prove
The crudest possible screen divides equity value by the latest quarter’s product sales annualized. On that basis Omeros trades at about 11.6 times, Travere at about 11.2 times on FILSPARI, Zevra at about 5.8 times on MIPLYFFA alone, and BioCryst at about 4.0 times total product sales. Annexon, Dianthus and InflaRx have no product sales and drop out of the calculation entirely.
What this screen is not. These are not comparable enterprise-value multiples. Cash, debt, other revenue lines, growth rates, tax assets, royalty structures and pipelines differ across all four companies. The screen has exactly one legitimate use: it locates where the market has already placed Omeros. And it has placed it closer to a premium growth franchise than to the closest launch-stage sales peer.
Arguments for the premium
- TA-TMA has no other FDA-approved treatment, and the first approved product can shape the treatment pathway rather than compete inside an existing one.
- Sequential growth from $9.9M to $28.5M is steep, and the second quarter covered its own reported operating costs.
- Reimbursement friction is falling in stages, with a permanent J-code in force and NTAP from October 1.
- The nearest randomized adult competitor missed its primary endpoint in July.
- Milestones, royalties and retained pipeline sit outside the revenue line entirely.
Arguments against it
- Two quarters is not a curve, and Q2 may contain launch and stocking effects that do not repeat.
- Early cost of sales is artificially low, so the eventual normalized margin is unknown.
- Europe is an active refusal, not a pending approval.
- Post-July cash is roughly $72M on the mechanical bridge, far below the June headline.
- The option stack and an untouched $150M ATM create real dilution paths, only partly offset by the remaining $90.1M of repurchase authorization.
A deliberately crude screen. These are not comparable enterprise-value multiples, and the three pre-revenue peers cannot appear at all.
Omeros ($OMER)11.6x
YARTEMLEA $28.5M annualized
Travere ($TVTX)11.2x
FILSPARI $141.1M annualized
Zevra ($ZVRA)5.8x
MIPLYFFA $30.2M annualized
BioCryst ($BCRX)4.0x
product sales $157.5M annualized
Source: SEC filings; prices at the close of August 26, 2026
17 Transaction precedents: useful ceilings, bad multiples
Chiesi agreed in April 2026 to acquire KalVista Pharmaceuticals at $27.00 per share in cash, described in the announcement as equity consideration of approximately $1.9 billion, and completed the acquisition in June. Biogen’s second-quarter accounting for the Apellis acquisition records total consideration of $5,410.1 million, comprising $5,406.0 million in cash and $4.1 million of contingent consideration.
Those transactions prove that strategic buyers pay real money for rare-disease franchises and complement assets. They do not imply a value for Omeros. The targets had different products, patent lives, cash positions, competitive sets and revenue trajectories, and each price embeds synergies available only to that acquirer. A control transaction also carries a premium that a minority public shareholder does not receive unless an acquisition actually happens.
Where precedents belong. In the optionality discussion, as evidence that the asset class has strategic buyers. Not in a base-case model, and never as a per-share target derived by scaling somebody else’s deal.
18 A valuation bridge instead of a price target
Merlintrader publishes no price target on $OMER and reproduces no analyst consensus, because a defensible target requires inputs that the current disclosure does not provide. Stating that plainly is more useful than a number built on assumptions that cannot be checked.
What a target would need. The diagnosed U.S. patient pool and treatment eligibility; center adoption, treatment duration, realized net price and normalized gross margin; a probability for Europe after re-examination; probability and timing for each Novo milestone and the royalty stream; an indication, cost and probability of success for OMS1029; and a complete treasury-stock dilution calculation on a pro-forma cash balance.
What is available today. Two commercial quarters, one balance sheet, a set of contingent contracts and a share price. Everything above the $114M annualized denominator, roughly $1,174M of enterprise value, is a claim on outcomes that have not happened yet.
The research task is therefore not to find a peer with the same market capitalization. It is to test whether that residual has enough probability-weighted content: how much launch growth, how much duration, how much margin, how much Europe, how much Novo. Each of those can be bounded. None of them can be replaced by a multiple.
19 Bull, base and bear over the next twelve to twenty-four months
These are operating states rather than price targets, and the revenue bands are deliberately wide. Their purpose is to name the facts that would move the thesis, not to predict a number.
Bull. Q2 was not a stocking peak; activated centers and repeat orders keep expanding; gross-to-net stays controlled and normalized margin holds up after preapproval inventory is exhausted; Europe turns positive or a credible resubmission path opens; at least one Novo milestone or pipeline event adds cash or probability. Commercially, YARTEMLEA moves beyond a $225M annualized pace within twenty-four months. The current premium then reads as payment for a scarce and growing orphan franchise.
Bear. Third and fourth quarter sales decelerate toward a weak repeat-order base; realized net price or treatment duration disappoints; the negative CHMP opinion is confirmed; real-world safety experience constrains use; Novo and pipeline milestones slip. The franchise cannot hold a $100M annualized pace, or holds it only with much heavier commercial spending than Q2 suggested. The premium compresses while option value is discounted and dilution returns to the foreground.
Base. Sales grow unevenly as centers onboard; NTAP helps selected hospitals from October; the European process stays unresolved or ends negatively; pipeline timing stays vague; no emergency financing is needed but the ATM remains a rational tool. Annualized sales settle in a broad $120M to $180M band before the next leg of adoption, and much of the residual value continues to depend on duration and options. The result is a volatile equity rather than a clean compounder.
Proof points and downgrade triggers
Proof. Sequential growth accompanied by center and patient breadth rather than dose intensity alone. Normalized gross margin that stays strong once preapproval inventory runs out. Operating cash near break-even without starving launch or research. A favorable European resolution or a clearly defined resubmission path. OMS1029 entering a named Phase 2 indication with funded development.
Downgrade. Two consecutive quarters of material deceleration with no timing explanation. Gross-to-net deterioration or treatment duration inconsistent with the economics. New safety evidence that changes prescribing behavior or labeling. Europe confirmed negative while guidance still capitalizes a near-term EU launch. Large ATM issuance without a value-accretive deployment plan.
20 Bottom line: a premium early launch that has to earn its residual
Omeros has done the hard part. YARTEMLEA is approved, commercially available, and generating material revenue in a disease that had no approved treatment before December 2025. The clinical signal is supported by an approved label, a 28-patient pivotal study and consistent observational experience, and it is not supported by any randomized head-to-head evidence. Europe is an active refusal under re-examination with structural objections that a re-examination cannot fully answer. The balance sheet is stronger than before the Novo transaction, and the June cash headline overstates post-July liquidity by roughly $60 million.
The best operating comparator is Zevra. The best scientific comparators are Annexon and Dianthus. The best maturity checks are BioCryst and Travere. InflaRx is the useful negative control. None of them is close enough to justify a one-step multiple, which is the whole point: a company with no perfect peer has to be valued by construction rather than by comparison.
Where the analysis stops. Omeros is no longer a binary development story, and at $18.22 the price already assumes meaningful success beyond a flat continuation of the second quarter. The next step up in analytical conviction should come from commercial-quality disclosure and a patient-based model, not from a higher share price, a transaction headline or a target scraped from an aggregator. This is analysis, not advice, and no part of it is a recommendation to buy, sell or hold any security.
Related Research On Merlintrader
- Company page: Omeros Corporation ($OMER) Stock Hub — filings, catalysts and every future update in one place.
- Sector index: Biotech Stock Hubs and 2026 catalysts.
- Ranking: Top Ten Biotech Stocks Right Now.
Primary Sources And Reference Links
- SEC Form 10-Q, quarter ended June 30, 2026 — product sales, gross-to-net, operating cash flow, convertible-note repurchase table, options, ATM facility, OMIDRIA arrangement and the Novo Nordisk terms.
- SEC-filed second-quarter 2026 earnings release — non-GAAP reconciliation and management commentary.
- 2026 definitive proxy statement — beneficial ownership at the April 17, 2026 record date.
- FDA prescribing information for YARTEMLEA — indication, dosing, efficacy and safety tables.
- FDA approval letter, December 23, 2025 — approval date and postmarketing requirements.
- FDA announcement of the first approved TA-TMA treatment.
- EMA Yartemlea page — negative CHMP opinion of June 25, 2026, grounds for refusal and re-examination status.
- Omeros announcement of permanent HCPCS code J1289.
- CMS FY2027 IPPS final-rule materials — New Technology Add-on Payment framework.
- Khaled et al., Journal of Clinical Oncology 2022 — the 28-patient pivotal study.
- Castelli et al., Bone Marrow Transplantation 2024 — 20-patient compassionate-use cohort.
- Schoettler et al., American Journal of Hematology 2025 — 136 patients from the expanded-access program.
- Zhang et al., Frontiers in Immunology 2021 — eculizumab meta-analysis, 116 patients.
- Acosta-Medina et al., American Journal of Hematology 2025 — 99-patient Mayo Clinic TA-TMA series.
- AstraZeneca update on the ravulizumab Phase 3 trial in HSCT-TMA.
- Peer operating facts: SEC filings for Zevra, Annexon, Dianthus, InflaRx, BioCryst and Travere.
- Transaction precedents: Chiesi and KalVista, and the Apellis consideration disclosed in Biogen’s second-quarter Form 10-Q.
Every figure above is taken from the document named beside it, with its own reference date. Scientific papers were located through the Consensus research index and then read and cited on the journal or DOI page. Market prices are Finviz Elite daily closes.
Get these reports in real time
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing above should be read as a recommendation to buy, sell or hold $OMER or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, regulatory agencies, peer-reviewed journals, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Omeros is a commercial-stage biotechnology company with a single approved product, an unresolved European application, contingent partner economics and an option-heavy capital structure. Companies of this kind can move violently on single clinical, regulatory or financing events, and the risk of permanent capital loss is real. Nothing above quantifies that risk for any individual reader.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
Omeros Corporation ($OMER) — peer and valuation deep dive, Merlintrader
Biotech Catalyst Calendar
PDUFA dates, AdCom meetings, clinical readouts and trial completions in one free, filterable calendar.
Open the calendar →
PDUFA dates, AdCom meetings, clinical readouts and trial completions in one free, filterable calendar.
Open the calendar →